1.Skov RL, Jensen KS. Community-associated methicillin-resistant Staphylococcus aureus as a cause of hospital-acquired infections. Journal of Hospital Infection 2009; 73: 364–370.
2.David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clinical Microbiology Reviews 2010; 23: 616–687.
3.Morin CA, Hadler JL. Population-based incidence and characteristics of community-onset Staphylococcus aureus infections with bacteremia in 4 metropolitan Connecticut areas, 1998. Journal of Infectious Diseases 2001; 184: 1029–1034.
4.Van De Griend P, et al. Community-associated methicillin-resistant Staphylococcus aureus, Iowa, USA. Emerging Infectious Diseases 2009; 15: 1582–1589.
5.El Atrouni WI, et al. Temporal trends in the incidence of Staphylococcus aureus bacteremia in Olmsted County, Minnesota, 1998 to 2005: a population-based study. Clinical Infectious Diseases 2009; 49: e130–138.
6.Kallen AJ, et al. Health care-associated invasive MRSA infections, 2005–2008. The Journal of the American Medical Association 2010; 304: 641–648.
7.Lessa FC, et al. Comparison of incidence of bloodstream infection with methicillin-resistant Staphylococcus aureus between England and United States, 2006–2007. Clinical Infectious Diseases 2010; 51: 925–928.
8.Tracy LA, et al. Staphylococcus aureus infections in US veterans, Maryland, USA, 1999–2008. Emerging Infectious Diseases 2011; 17: 441–448.
9.Buss BF, et al. Population-based estimates of methicillin-resistant Staphylococcus aureus (MRSA) infections among high school athletes – Nebraska, 2006–2008. Journal of School Nursing 2009; 25: 282–291.
10.Caffrey AR, Laplante KL. Changing epidemiology of methicillin-resistant Staphylococcus aureus in the Veterans Affairs Healthcare System, 2002–2009. Infection. Published online: 13 December 2011. doi:10.1007/s15010-011-0232-3.
11.Crum NF, et al. Fifteen-year study of the changing epidemiology of methicillin-resistant Staphylococcus aureus. American Journal of Medicine 2006; 119: 943–951.
12.Frei CR, et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus skin and soft tissue infections as a common cause of hospitalization in United States children. Journal of Pediatric Surgery 2010; 45: 1967–1974.
13.Li F, Miller FD, Effler PV. Epidemiology of methicillin-resistant Staphylococcus aureus among incarcerated population in Hawai'i, 2000–2005. Hawai'i Journal of Medicine & Public Health 2010; 69: 99–102.
14.Schneider-Lindner V, et al. Antibacterial drugs and the risk of community-associated methicillin-resistant Staphylococcus aureus in children. Archives of Pediatrics and Adolescent Medicine 2011; 165: 1107–1114.
15.Klevens RM, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. Journal of the American Medical Association 2007; 298: 1763–1771.
16.Liu C, et al. A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco, 2004–2005. Clinical Infectious Diseases 2008; 46: 1637–1646.
17.Klein E, Smith DL, Laxminarayan R. Community-associated methicillin-resistant Staphylococcus aureus in outpatients, United States, 1999–2006. Emerging Infectious Diseases 2009; 15: 1925–1930.
18.Mera RM, et al. Increasing role of Staphylococcus aureus and community-acquired methicillin-resistant Staphylococcus aureus infections in the United States: a 10-year trend of replacement and expansion. Microbial Drug Resistance 2011; 17: 321–328.
19.Farr AM, et al. Trends in hospitalization for community-associated methicillin-resistant Staphylococcus aureus in New York City, 1997–2006: data from New York State's Statewide Planning and Research Cooperative System. Infection Control and Hospital Epidemiology 2012; 33: 725–731.
20.Fridkin SK, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. New England Journal of Medicine 2005; 352: 1436–1444.
21.Schwartz BS, et al. Body Mass Index and the Built and Social Environments in Children and Adolescents Using Electronic Health Records. American Journal of Preventive Medicine 2011; 41: e17–e28.
22.Morrison MA, Hageman JC, Klevens RM. Case definition for community-associated methicillin-resistant Staphylococcus aureus. Journal of Hospital Infection 2006; 62: 241.
23.Liu AY, et al. Associations of the burden of coal abandoned mine lands with three dimensions of community context in Pennsylvania. ISRN Public Health 2012; 2012: 11.
24.Feinstein AR, Horwitz RI. An algebraic analysis of biases due to exclusion, susceptibility, and protopathic prescription in case-control research. Journal of Chronic Diseases 1981; 34: 393–403.
25.Huang H, et al. Comparisons of community-associated methicillin-resistant Staphylococcus aureus (MRSA) and hospital-associated MSRA infections in Sacramento, California. Journal of Clinical Microbiology 2006; 44: 2423–2427.
26.Kim J, et al. Changing epidemiology of methicillin-resistant Staphylococcus aureus in Alberta, Canada: population-based surveillance, 2005–2008. Epidemiology and Infection 2011; 139: 1009–1018.
27.Klevens RM, et al. Community-associated methicillin-resistant Staphylococcus aureus and healthcare risk factors. Emerging Infectious Diseases 2006; 12: 1991– 1993.
28.Kuehnert MJ, et al. Methicillin-resistant Staphylococcus aureus hospitalizations, United States. Emerging Infectious Diseases 2005; 11: 868–872.
29.Naimi TS, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. Journal of the American Medical Association 2003; 290: 2976–2984.
30.Schneider-Lindner V, et al. Antimicrobial drugs and community-acquired methicillin-resistant Staphy lococcus aureus, United Kingdom. Emerging Infec tious Diseases 2007; 13: 994–1000.
31.Methicillin-resistant Staphylococcus aureus among players on a high school football team – New York City, 2007. Morbidity and Mortality Weekly Report 2009; 58: 52–55.
32.Khawcharoenporn T, et al. Risk factors for community-associated methicillin-resistant Staphylococcus aureus cellulitis--and the value of recognition. Hawai'i Journal of Medicine and Public Health 2010; 69: 232–236.
33.Morrison-Rodriguez SM, et al. Community-associated methicillin-resistant Staphylococcus aureus infections at an Army training installation. Epidemiology and Infection 2010; 138: 721–729.
34.Bagger JP, Zindrou D, Taylor KM. Postoperative infection with meticillin-resistant Staphylococcus aureus and socioeconomic background. Lancet 2004; 363: 706–708.
35.Larsen AR, et al. Emergence and characterization of community-associated methicillin-resistant Staphyloccocus aureus infections in Denmark, 1999 to 2006. Journal of Clinical Microbiology 2009; 47: 73–78.
36.Skiest DJ, et al. Prospective comparison of methicillin-susceptible and methicillin-resistant community-associated Staphylococcus aureus infections in hospitalized patients. Journal of Infection 2007; 54: 427–434.
37.Como-Sabetti KJ, et al. Risk factors for community-associated Staphylococcus aureus infections: results from parallel studies including methicillin-resistant and methicillin-sensitive S. aureus compared to uninfected controls. Epidemiology and Infection 2011; 139: 419– 429.
38.Hankin A, Everett WW. Are antibiotics necessary after incision and drainage of a cutaneous abscess? Annals of Emergency Medicine 2007; 50: 49–51.
39.Rajendran PM, et al. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrobial Agents and Chemotherapy 2007; 51: 4044–4048.
40.Tognetti L, et al. Bacterial skin and soft tissue infections: review of the epidemiology, microbiology, aetiopathogenesis and treatment: A collaboration between dermatologists and infectivologists. Journal of the European Academy of Dermatology and Venereology. Published online: 7 January 2012. doi:10.1111/j.1468-3083.2011.04416.x.
41.Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clinical Infectious Diseases 2003; 36: 131–139.